TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04285138

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: phantom limb exercise
Description: phantom limb exercises (that is, active imaginal efforts to move the phantom), under the assumption that the neural pathways involved in performing actual movements are activated when using one's imagination to move the phantom extremity

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional treatment
Description: Mirror therapy uses a flat mirror placed parasagittally in front of the patient's body with the reflective surface toward the sound limb so that the amputee sees the reflection of the sound limb in the mirror \[Figure 1\]. This reflection mimics the amputated limb, and with the movement of the intact limb, the mirror provides an optical illusion that the phantom limb is moving simultaneously.~Equipment:~Therapy mirror: A standing mirror (130 cm × 46 cm) with wooden frame and base (62 cm × 65 cm) Routine physiotherapy The general exercise programme consisted of strengthening, stretching, dynamic, and isometric exercises based on the level of amputation and their assessment results. Participants allocated to the control group were advised to continue rehabilitation at their respective physiotherapy out-patient departments as frequently as possible. Participants were given a diary and advised to record their activities, specifying the nature, frequency and duration of each activity
Study: NCT03023995

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CAF with connective tissue graft
Description: In control group, connective tissue graft was harvested, after which the flap was coronally positioned over the graft to completely cover it and secured with 4-0 non resorbable.
Study: NCT02008526

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Messages Transmitted by Peer Health Educators (TXT-PHE)
Description: Participants receive five gay-specific, theory-based pre-written messages per day sent on a predetermined schedule. Participants who respond to the pre-written text messages or initiate queries or requests for support (pull) are sent additional real-time messages back from the PHE. Text messages are transmitted and responded to in real time, at the peak hours of high-risk activities. During the 8-week intervention, participants receive a brief weekly text-based assessment on their methamphetamine use and HIV sexual behaviors in the previous seven days.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Messages Transmitted by Automation (TXT-Auto)
Description: Participants receive five gay-specific, theory-based pre-written messages per day sent on a predetermined schedule. During the 8-week intervention, participants receive a brief weekly text-based assessment on their methamphetamine use and HIV sexual behaviors in the previous seven days.
Study: NCT02816723

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Stress Reduction
Description: mindfulness/meditation/movement training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brain Health
Description: Brain Health Education
Study: NCT01806181

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Study: NCT02845674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTX-101 0.09%
Description: 0.09% cyclosporine nanomicellar solution
Study: NCT02139397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFMO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Study: NCT03618875

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ice pack
Description: ice pack was placed on eyelid 5 minutes prior to IVIT

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: room temperature pack
Description: room temperature pack was placed on eyelid 5 minutes prior to IVIT
Study: NCT00176449

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion SR
Description: 150mg twice a day (starting with 150mg once a day for three days)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Comparable placebo
Study: NCT03406520

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chlorhexidine-impregnated disk
Description: The chlorhexidine-impregnated sponge, named biopatch, is a protective disk (2.5 cm x 0.7 cm), which is hydrophilic polyurethane absorptive foam with chlorhexidine gluconate, in average of 86.8mg per disk
Study: NCT03699748

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lay Health Worker Intervention
Description: Patients randomized into the intervention will be assigned a lay health worker who will contact the patient to begin the intervention. The intervention includes: education on early advance care planning, documenting goals of care, assessing symptoms, and coordinating community services (such as home health, home visits, and home hospice). The intervention is provided along with usual care as provided by Unite Here Health and local oncologists.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care as provided by Unite Here Health and local oncologists

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Usual care as provided by Unite Here Health and local oncologists
Study: NCT04346316

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SHR0302
Description: Oral tablets taken once daily (QD)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SHR0302
Description: Oral tablets taken once daily (QD)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SHR0302
Description: Oral tablets taken once daily (QD)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SHR0302
Description: Oral tablets taken once daily (QD)
Study: NCT04294277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib
Description: At Day 1, prior to the start of treatment, results from screening visit evaluations are reviewed to determine eligibility requirements. Subsequent visits during treatment phase will take place at Day 8, Day 15 and Day 21 and subsequently at 3 week intervals. Timing of subsequent visits can be prolonged to max. 9 week intervals if no problems exist during the first 12 weeks of therapy. Subjects will self-administer study drug using an oral QD regimen in a continuous dosing schedule. Each dose of Pemigatinib should be taken first thing in the morning upon waking or after a 2-hour fast; subjects should then fast for an additional 1 hour after taking study drug. The starting dose is 13.5 mg Pemigatinib. Study treatment will continue until 12 months, or until the evidence of disease relapse or onset of unacceptable toxicity.
Study: NCT00296517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 323U66 (Bupropion Hydrochloride Sustained Release)
Description: Subjects with Major Depressive Disorder who were randomized to take 100mg of Bupropion SR in the morning and placebo in the evening for one week. Week 2 subjects were given 100mg dose of Bupropion morning and evening. Weeks 3 thru 12 received 150mg dose morning and evening. Week 1=dose level 1, 100 mg. Week 2=dose level 2, 200 mg. Weeks 3 - 12=dose level 3, 300 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects with Major Depressive Disorder who were randomised to placebo to match Bupropion SR during the treatment period.
Study: NCT01700491

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epidural Catheter 0.2% ropivacaine
Description: 0.2% ropivacaine into epidural space and saline into paravertebral space

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paravertebral Catheter 0.4% ropivacaine
Description: 0.4% ropivacaine into paravertebral space and saline into the epidural space
Study: NCT02814526

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Moderate/high intensity aerobic exercise will involve training at 70-80% heart rate reserve for 30 min, with an additional 10 minutes for warm-up and 5 minutes for cool-down, 4 times per week, for 12 months while supervised twice per week by a study-certified trainer at a participating YMCA .

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching/balance/range of motion exercise
Description: The stretching/balance/range of motion program will involve exercise at or below 35% heart rate reserve for 30 min, with an additional 10 minutes for warm up and 5 minutes for cool-down, 4 times per week, for 12 months while supervised twice per week by a study-certified trainer at a participating YMCA.
Study: NCT01769547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dovitinib
Description: Treatment continued until Disease Progression, Toxicity, or patient withdrawal.
Study: NCT01621009

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active bupropion + counseling
Description: Medications-Pre-quit: 150 mg bupropion per day 7 days before quit attempt, then 150 mg twice daily for 4 days before quit attempt; then 150 mg bupropion twice daily for eight weeks.~Counseling-Pre-quit: two 10 minutes sessions before quit date; eight 10-minute sessions post quit date.
Study: NCT04484103

Intervention type: OTHER
Intervention: Assessment of the diagnostic performance of the PI-RADS score (as a stand-alone) and of the RPCRC for predicting the presence of ISUP ≥2 prostate cancer at subsequent biopsy in 251 patients.
Description: The following features will be retrieved from the CRFs of the patients included in the MRI-FIRST trial: age, DRE findings, PSA level, prostate volume, maximal PI-RADS score; the history of biopsy will be set to a default value of none since all patients included in the MRI-FIRST trial were biopsy naïve.~Then, the RPCRC will be used to calculate two different risks: the risk of detectable prostate cancer and of significant prostate cancer (ISUP ≥2) at subsequent biopsy.~The PI-RADS score (as a stand-alone) and the risks predicted by the RPCC will be compared to the results of the prostate biopsy performed during the MRI-FIRST trial.~Throughout the study, the version 2 of the PI-RADS score will be used.
Study: NCT01621009

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active bupropion, No counseling
Description: Medication - 150 mg bupropion per day starting week before quit day, then 150 mg twice daily 3 days before quit day, then 150 mg twice daily for eight weeks after quit day.~Counseling: No cessation counseling, only medication checks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo medication + counseling
Description: Placebo bupropion once daily 7 days before quit day, then twice daily 4 days before quit attempt, then twice daily for 8 weeks after quit day.~Counseling: Two 10-minutes sessions before quit day, then eight 10-minutes sessions for eight weeks after quit day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo medication, No counseling
Description: Pre-quit: Placebo medication once daily 7 days before quit day, then twice daily before quit day, then twice daily for 8 weeks after quit day.~Counseling: No counseling, just medication checks
Study: NCT02147301

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LC Bead
Description: Doxorubicin Eluting Bead Transarterial Chemoembolization (DEB-TACE):~Doxorubicin-loaded LC Beads® are administered via a co-axially placed commercially available hepatic artery catheter into hepatic arteries targeted for treatment. Procedure is performed under direct fluoroscopic visualization until stasis of arterial flow is achieved or until a total of 4 ml of microspheres have been administered, whichever occurs first.
Study: NCT02771756

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: zhen qishen capsule and Oral Supplement of Yuyikang

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: zhen qishen capsule placebo and Oral Supplement of Yuyikang placebo

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: chemotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: chemotherapy

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: nutrition education

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nutrition education
Study: NCT01357772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT01551667

Intervention type: BIOLOGICAL
Intervention: Antibody assays for S. aureus
Description: Antibody assays for S. aureus at Day 0, Day 2, Day 4, Day 7, Day 30 and Month 6.
Study: NCT03041051

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV13

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PPV23
Study: NCT05014711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Before infusion, remifentanil is given 0.3 g/kg slowly intravenous injection more than 60 seconds, and the initial dose is 0.025ug/kg/min. The dosage is adjusted to achieve the target depth of analgesia and sedation (CPOT \< 3, RASS -2 to 1), with each change 0.025ug/kg/min and the maximum dose 0.15ug/kg/min.
Study: NCT01551667

Intervention type: BIOLOGICAL
Intervention: Antibody assays for S. aureus
Description: Antibody assays for S. aureus at Day 0, Day 2, Day 4, Day 7, Day 30 and Month 6.

Intervention type: BIOLOGICAL
Intervention: Basic blood work
Description: Hemogramme + CRP on Days 0, 2, 4 and 7

Intervention type: BIOLOGICAL
Intervention: Basic blood work
Description: Hemogramme + CRP on Days 0, 2, 4 and 7
Study: NCT00004233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triacetyluridine
Study: NCT02774889

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stepping Online
Description: Stepping Online is a password-protected website with Stepping On graduates, whose groups are randomized to Stepping Online and will have access to and training in a password-protected website. The website includes:~1. Fall prevention tips~2. Fall prevention exercise videos with narrations for proper technique and safety precautions~3. Guest expert videos with online access to the guest expert to ask questions~4. Tools to set exercise goals, get reminders and track progress~5. Access to a fall prevention specialist for personal feedback and suggested group homework~6. Group discussion and messaging (one-to-one and with their fellow Stepping On workshop participants group, or with all Stepping Online participants and leaders)~7. Fall prevention resources
Study: NCT01213238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 140 mg/m2 by Hepatic Arterial Catheter (HAI) on day 1 of a 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 140 mg/m2 by Hepatic Arterial Catheter (HAI) on day 1 of a 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Starting dose of 500 mg/m2 by mouth twice daily, on days 1 - 14 of a 21 day cycle.
Study: NCT05014711

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Before infusion, fentanyl is given 0.3 g/kg slowly intravenous injection more than 60 seconds, and the initial dose is 0.025ug/kg/min. The dosage is adjusted to achieve the target depth of analgesia and sedation (CPOT \< 3, RASS -2 to 1), with each change 0.025ug/kg/min and the maximum dose 0.15ug/kg/min.
Study: NCT01213238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Starting dose of 500 mg/m2 by mouth twice daily, on days 1 - 14 of a 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10 mg/kg by vein on day 1 of a 21 day cycle.
Study: NCT01178788

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 17 alpha-hydroxy progesterone caproate
Description: weekly injection of 17 P

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: micronized Progesterone
Description: daily administration of vaginal progesterone

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Study: NCT04260113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate
Description: Apatinib orally 500mg once daily half an hour after meal
Study: NCT04227834

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health hygiene education
Description: A cartoon video explaining the etiology, risk factors, clinical symptoms, treatment and prevention of helminthiasis were given to the school-aged children

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health hygiene education
Description: A cartoon video explaining the etiology, risk factors, clinical symptoms, treatment and prevention of helminthiasis were given to the school-aged children
Study: NCT04368169

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Teramune Botanical Extract
Description: Combination blend of aromatic plant extracts in an emulsifier carrier.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Emulsifier carrier without active supplement ingredients.
Study: NCT02650375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metatinib Tromethamine
Description: Patients receive Metatinib orally 200mg once daily (QD) or 100mg twice daily (BID) until disease progression or unacceptable toxicity occurred.
Study: NCT03241693

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blended-learning in ethics
Description: Experimental group followed clinical practices in hospital centers during 8 months.~In addition, an online specific syllabus about Professional Ethics was developed. It consisted of 6 themes and included topics as moral values, ethics and moral, bioethics and professional ethics, ecc. Six online related activities were created: to solve situations related to real clinical practices. Six face to face group sessions based on cooperative learning were planned in order to discuss ethical issues detected among clinical practices during 4 months. Students were divided in small groups, 4-5 participants each, and active participation techniques were used.

Intervention type: OTHER
Group type: OTHER
Intervention: control group
Description: Control group followed clinical practices in hospital centers during 8 months as usual.~In the control group, case study method was also used, thus students in control group had to create and perform a public exposition of a real clinical case about professional ethics. Cases had to be related to clinical practices in order to recognize ethical situations in the work environment. Neither online learning nor online activities were carried out.
Study: NCT01047319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Laquinimod
Description: One capsule containing 0.6 mg laquinimod to be administered orally once daily.
Study: NCT03880474

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-NP+M1
Description: Trial Vaccine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Sodium Chloride Placebo
Study: NCT03150459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg
Description: Simvastatin 20 mg/day for 12 weeks (Group 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin 40mg
Description: Simvastatin 40 mg/day for 12 weeks (Group 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin 400 mg
Description: Rifaximin 400 mg/8 hours for 12 weeks (Group 1 and 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin 400 mg
Description: Rifaximin 400 mg/8 hours for 12 weeks (Group 1 and 2)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Simvastatin
Description: Placebo of Simvastatin for 12 weeks (Group 3)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Rifaximin
Description: Placebo of Rifaximin for 12 weeks (Group 3)
Study: NCT02273167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NER1006, 2-Day Split-Dosing
Description: The subject will self-administer the first dose of the assigned investigational product in the evening prior to the scheduled colonoscopy and take mandatory additional clear fluid. Subject will take the second dose together with mandatory additional clear fluids on the morning of the colonoscopy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NER1006,1-Day Morning Split-Dosing
Description: The subject will self-administer the first dose of the investigational product on the morning of the colonoscopy and take mandatory additional clear fluid.~After a 1-2 hour break the subject will self-administer the second dose plus additional clear mandatory fluid.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MOVIPREP, 2-Day Split-Dosing
Description: The subject will self-administer the first dose of the assigned investigational product in the evening prior to the scheduled colonoscopy and take recommended additional clear fluid. Subject will take the second dose together with recommended additional clear fluids on the morning of the colonoscopy.
Study: NCT04539990

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral treatment for sleep difficulties
Description: This intervention is mediated by the parents. Parents are educated regarding sleep hygiene and instructed to follow simple rules which create a reliable evening routine and reduce exposure to stimulating factors that delay sleep onset (e.g., caffeine or exercise). In addition, parents are asked to initiate a fading behavioral protocol whereby they teach their child to fall asleep independently, with less parental attention. This requires parents to limit their interaction with their child after the children are put to bed so as not to interfere with sleep onset. This includes limiting conversations and lying in bed with the child. This behavioral approach is applied gradually and is expected to reduce the time it takes children to fall asleep.
Study: NCT03228030

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Thiamine
Description: Capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical capsules
Study: NCT04312100

Intervention type: OTHER
Intervention: oxygen treatment
Description: different kinds of oxygen treatments will be given to patients according to their state of illness

Intervention type: OTHER
Intervention: oxygen treatment
Description: different kinds of oxygen treatments will be given to patients according to their state of illness

Intervention type: OTHER
Intervention: oxygen treatment
Description: different kinds of oxygen treatments will be given to patients according to their state of illness
Study: NCT04176224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-1186
Description: Suspension